Recent significant events surround Edwards Lifesciences Corporation (EW). The company has been criticized by investors and is facing multiple class-action lawsuits for securities fraud. Despite negative market reactions and a substantial loss of market capitalization, they've reported robust earnings growth over the past three years. A primary concern is around the performance of their Transcatheter Aortic Valve Replacement (TAVR) platform, with fears that Wall Street might be bearish on the prospects. Notwithstanding these difficulties, the company’s 2025 fiscal year looks promising. Edwards Lifesciences has announced its Q4 earnings, which surpassed Wall Street projections. The company also held its annual investor conference where it laid out its growth strategy, with strong growth in Transcatheter Mitral and Tricuspid therapies (TMTT) sales being a highlight. Additionally, the company has completed the sale of its Critical Care product group to Becton, Dickinson and Company (BD). Institutional investors own 85% of the company, with Vanguard Group and Savant Capital being notable stakeholders. Lastly, firm plans for a major update in heart tech are set to be revealed on February 11th.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 22 Feb 2025 03:50:00 GMT -
Rating -2
- Innovation 8
- Information 6
- Rumor -5
